Understanding Intrinsic & Extrinsic Resistance to RAS Inhibitors to Improve Depth & Durability of Response
- Understanding how tumor cell-instrinsic and microenvironmental mechanisms limit response of KRAS-mutant lung cancers to RAS inhibitors
- Targeting adaptive vulnerabilities conferred by co-occurring genomic alterations in KRAS-mutant lung cancers
- Improving suppression of KRAS and downstream growth and survival pathways